Case Study: Leading Biopharmaceutical Company achieves faster, AI-augmented oncology competitive insights with IQVIA Asset Intelligence

Biopharmaceutical company gains a comprehensive competitive analysis for their oncology products

Leading Biopharmaceutical Company needed indication-specific pricing and reimbursement insights for its oncology drugs across key markets (US, Canada, Japan, France, Germany, Italy, Spain and the UK). They engaged IQVIA to perform a health technology assessment (HTA), deliver a competitive landscape assessment for two oncology assets, estimate probability of technical and regulatory success (PTRS), predict approval dates and phase transitions, and co-develop an AI-augmented platform to support access, pricing and evidence planning.

IQVIA deployed its Asset Intelligence tool together with data science and NLP to aggregate IQVIA and public data, build and test multiple ML models, run simulations and validate outputs for competitor PTRS and market-entry scenarios. The work produced predicted PTRS scores, estimated approval timelines and identified additional competitive risks, saving the client months of research, enabling informed roadmap decisions, and delivering a prototype V&A platform with plans for ongoing collaboration with IQVIA.